2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2022
Imaging Modalities for Acute Tubulointerstitial Nephritis
Baker M, Perazella M. Imaging Modalities for Acute Tubulointerstitial Nephritis. 2022, 257-266. DOI: 10.1007/978-3-030-93438-5_20.ChaptersAcute tubulointerstitial nephritisTubulointerstitial nephritisAcute kidney injury diagnosisNonspecific constitutional symptomsChronic kidney diseaseImaging modalitiesCurrent imaging modalitiesEmission Tomography ImagingPositron emission tomography (PET) imagingNon-invasive diagnosisConstitutional symptomsFlank painMost patientsKidney diseaseKidney failureCase reportInjury diagnosisRadiographic cluesClinical dataCommon causeGallium uptakeCharacteristic signsSymptomsDiagnosisTomography imaging
2021
Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations
Perazella MA, Sprangers B. Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. Clinical Kidney Journal 2021, 14: 1301-1306. PMID: 33970161, PMCID: PMC8087122, DOI: 10.1093/ckj/sfab052.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsAcute tubulointerstitial nephritisKidney biopsyImmune-related adverse eventsVall d'Hebron University HospitalSingle-center studyNoninvasive diagnostic markerEvidence-based recommendationsAKI patientsICI rechallengeNephrology servicesCheckpoint inhibitorsICI treatmentKidney injuryAdverse eventsTubulointerstitial nephritisNonhematologic malignanciesUniversity HospitalTreatment protocolClinical practicePatientsOptimal managementDiagnostic markerCancer treatment